Legato Capital Management LLC Boosts Stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Legato Capital Management LLC increased its holdings in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 60.9% during the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 29,699 shares of the company's stock after purchasing an additional 11,238 shares during the period. Legato Capital Management LLC owned 0.06% of Amphastar Pharmaceuticals worth $861,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the business. Signaturefd LLC boosted its position in Amphastar Pharmaceuticals by 147.7% during the 1st quarter. Signaturefd LLC now owns 872 shares of the company's stock valued at $25,000 after acquiring an additional 520 shares in the last quarter. GF Fund Management CO. LTD. bought a new position in Amphastar Pharmaceuticals in the fourth quarter worth about $38,000. Tower Research Capital LLC TRC boosted its holdings in shares of Amphastar Pharmaceuticals by 43.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,145 shares of the company's stock valued at $43,000 after buying an additional 348 shares in the last quarter. IFP Advisors Inc purchased a new position in shares of Amphastar Pharmaceuticals in the 1st quarter worth approximately $34,000. Finally, GAMMA Investing LLC raised its stake in shares of Amphastar Pharmaceuticals by 46.6% during the 1st quarter. GAMMA Investing LLC now owns 1,333 shares of the company's stock worth $39,000 after acquiring an additional 424 shares in the last quarter. Institutional investors own 65.09% of the company's stock.

Amphastar Pharmaceuticals Stock Performance

Shares of AMPH traded down $0.14 during trading hours on Friday, reaching $22.37. 329,130 shares of the company traded hands, compared to its average volume of 494,964. The company has a quick ratio of 2.02, a current ratio of 2.95 and a debt-to-equity ratio of 0.80. The business has a fifty day moving average price of $24.01 and a 200-day moving average price of $27.30. Amphastar Pharmaceuticals, Inc. has a 12-month low of $20.43 and a 12-month high of $53.96. The stock has a market capitalization of $1.05 billion, a P/E ratio of 8.11 and a beta of 0.72.

Analysts Set New Price Targets

Several brokerages have weighed in on AMPH. JPMorgan Chase & Co. restated a "neutral" rating and issued a $30.00 target price (down from $45.00) on shares of Amphastar Pharmaceuticals in a research note on Monday, May 12th. Wells Fargo & Company reduced their target price on Amphastar Pharmaceuticals from $40.00 to $35.00 and set an "overweight" rating on the stock in a research report on Thursday, May 8th. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Amphastar Pharmaceuticals in a research note on Thursday, April 10th. Four investment analysts have rated the stock with a hold rating and one has issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $32.33.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.